Gilead Sciences (NQ:GILD)

Vir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D Treatment ↗

Topics Stocks

November 09, 2026

Vir stock catapulted to a nearly two-year high Monday on a "clean win" for its experimental hepatitis D treatment.

Via Investor's Business Daily

Compugen (CGEN) Q3 2026 Earnings Call Transcript ↗

November 09, 2026

Enrollment in the MAIA-Ovarian trial is complete and data is due by early 2027.

Gilead Sciences (NASDAQ:GILD) Posts Q3 Beat but Shares Stay Flat as Raised Guidance Is Roughly In Line ↗

Topics Earnings

Gilead Sciences (NASDAQ:GILD): A Dividend Quality Candidate for Income Investors ↗

October 31, 2026

Via Chartmill

October 29, 2026

Via Chartmill

Gabelli Releases Agenda for 8th Annual Healthcare Symposium

November 09, 2026

From Gabelli Funds

Via GlobeNewswire

The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation ↗

November 08, 2026

These are among the best the industry has to offer.

New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention

Topics Intellectual Property

November 06, 2026

Gilead deal and 2028 cash runway frame upcoming hepatitis data.

Vir Bio (VIR) Q3 2026 Earnings Call Transcript ↗

November 05, 2026

Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)

Topics Earnings

November 05, 2026

Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe. ↗

November 05, 2026

Gilead Sciences increased its quarterly dividend by 3.8% this year.

Vir Biotechnology (NASDAQ:VIR) expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the...

What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call ↗

November 05, 2026

Via MarketBeat

Topics Earnings

3 S&P 500 stocks we think twice about

November 04, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026

Topics Stocks

November 04, 2026

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...

2 Nasdaq 100 stocks to own for decades and 1 we brush off

November 02, 2026

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should ...

Topics Artificial Intelligence

United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect

November 02, 2026

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be announcing earnings results this Wednesday afternoon. Here’s what to expect. Myriad Genetics mi...

Earnings to watch: Myriad Genetics (MYGN) reports Q3 results tomorrow

November 02, 2026

Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow

November 02, 2026

Biotech company Amgen (NASDAQ:AMGN) will be reporting results this Tuesday after market hours. Here’s what you need to know. Amgen beat analysts’ revenue exp...

Amgen (AMGN) reports Q3: everything you need to know ahead of earnings

November 01, 2026

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results tomorrow after market hours. Here’s what investors should know. Bio...

BioMarin Pharmaceutical (BMRN) Q3 earnings: what to expect

November 01, 2026

The company is having a great year.

1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in November ↗

November 01, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market close. Here’s what to expect. Vertex Pharma...

Topics Artificial Intelligence

Vertex Pharmaceuticals earnings: what to look for from VRTX

October 31, 2026

Topics Artificial Intelligence

Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences

October 30, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 6.8% year on year...

GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loom

October 30, 2026

Base business sales surged 16%, marking strongest growth in over a decade.

S&P 500 Gap Movers for October 30, 2026 ↗

October 30, 2026

Via Chartmill

Topics Stocks

Gilead (GILD) Q3 2026 Earnings Call Transcript ↗

October 30, 2026

Gilead Sciences (NASDAQ:GILD) reported third-quarter 2026 base business sales growth of 16% year over year, its strongest growth rate in more than a decade, as HIV products, TRODELVY and Livdelzi drove...

Topics Earnings

S&P 500 Premarket Gainers and Losers on Oct. 30, 2026 ↗

October 30, 2026

Via Chartmill

Topics Stocks

What Gilead Sciences (GILD) Said on Its Q3 Earnings Call ↗

October 29, 2026

Via MarketBeat

Topics Earnings

After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fall ↗

October 29, 2026

Via Chartmill

Topics Stocks

Gilead Sciences (NASDAQ:GILD) surprises with Q3 2026 sales, full-year outlook slightly exceeds expectations

October 29, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 6.8% year on year to $8.3 billion...